Table 2. Patient, disease, and treatment characteristics.
| Patient | Age (y), Sex | Disease, Phase | Prior intensive chemotherapy | Interval from last intensive chemotherapy | Chemotherapy during study |
|---|---|---|---|---|---|
| 1 | 22, M | AML, Induction | - | - | 7+3 |
| 2 | 60, M | AML, Re-induction | Yes | 0.5 months | MEC |
| 3 | 68, F | AML, Re-induction | Yes | 7 months | Clo/Ara-C |
| 4 | 36, F | ALL, Induction | - | - | GRAAL [20] |
| 5 | 52, F | ALL, Induction | - | - | PETHEMA [21] |
| 6 | 35, M | AML, Re-induction | Yes | 7 months | Clo/Ara-C |
| 7 | 67, F | AML, Induction | - | - | 7+3 |
| 8 | 74, F | AML, Induction | - | - | 7+3 |
| 9 | 58, F | AML, Induction | - | - | 7+3 |
| 10 | 50, F | AML, Re-induction | Yes | 6 months | MEC |
| 11 | 65, M | AML, Re-induction | Yes | 4 months | MEC |
| 12 | 73, M | AML, Induction | - | - | 7+3 |
| 13 | 51, F | AML, Induction | - | - | 7+3 |
| 14 | 53, M | ALL, Induction | - | - | GRAAL |
| 15 | 23, M | ALL, Induction | - | - | PETHEMA |
| 16 | 52, F | AML, Induction | - | - | 7+3 |
| 17 | 52, F | AML, Re-induction | Yes | 10 months | MEC |
| 18 | 68, M | AML, Induction | - | - | 7+3 |
| 19 | 22, M | AML, Re-induction | Yes | 4 months | MEC |
| 20 | 61, F | AML, Induction | - | - | 7+3 |
7+3: Idarubicin + Cytarabine; ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; Clo/Ara-C: Clofarabine + Cytarabine; F: Female; M: Male; MEC: Mitoxantrone + Etoposide + Cytarabine